Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHA1813 vs Investigator's Choice in Recurrent/Progressive High-Grade Meningioma
NCT06739213Phase 2Not yet recruiting
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of SYHA1813 in meningioma (2 arms), sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd. Primary endpoint: Progression-Free Survival rate at 6 months. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
SYHA1813
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT06739213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739213.